Journal ArticleDOI
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Reads0
Chats0
About:
This article is published in Yearbook of Oncology.The article was published on 2010-01-01. It has received 850 citations till now. The article focuses on the topics: Dasatinib & Imatinib.read more
Citations
More filters
Dissertation
Personalized Medicine Support System for Chronic Myeloid Leukemia Patients
TL;DR: This document summarizes current capabilities, research and operational priorities, and plans for further studies that were established at the 2015 USGS workshop on quantitative hazard assessments of earthquake-triggered landsliding and liquefaction in the Central American region.
Journal ArticleDOI
Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States
Dominick Latremouille-Viau,Annie Guerin,Roy Nitulescu,Patrick S Gagnon,George J Joseph,Lei Chen +5 more
TL;DR: Dasatinib was associated with an increased hazard of dose decrease and switching to another TKI and higher healthcare costs, vs nilotinib, and there was no significant difference in TKI adherence levels and HRU levels.
Book ChapterDOI
Predictive genomic biomarkers.
Rakesh Kumar,Rafael G. Amado +1 more
TL;DR: This review will examine relevant examples of selection markers effectively utilized in oncology, and discuss important considerations pertaining to the co-development of drugs and diagnostics, including current regulatory paths, the incorporation of selection marker emerging late in development, and future directions in the area of personalized oncologists.
Journal ArticleDOI
Imatinib in the treatment of chronic myeloid leukemia in children and adolescents is effective and well tolerated: Report of the Polish Pediatric Study Group for the Treatment of Leukemias and Lymphomas.
Małgorzata Janeczko-Czarnecka,Maryna Krawczuk-Rybak,Irena Karpińska-Derda,Maciej Niedźwiecki,Katarzyna Musioł,Magdalena Ćwiklińska,Katarzyna Drabko,Katarzyna Mycko,Tomasz Ociepa,Katarzyna Pawelec,Danuta Januszkiewicz-Lewandowska,Marek Ussowicz,Blanka Rybka,Renata Ryczan-Krawczyk,Andrzej Kołtan,Grażyna Karolczyk,Agnieszka Zaucha-Prażmo,Wanda Badowska,Krzysztof Kałwak +18 more
TL;DR: The results confirm that the introduction of TKI therapy has revolutionized the treatment of CML in the pediatric population by replacing the previous method of treatment with HSCT and allowing a high percentage of OS and EFS.
Journal ArticleDOI
Monitoring and defining early response: Where to draw the line?
TL;DR: The evidence for the importance of the early assessment of response for treatment change decisions, the emerging evidence for incorporating additional sample collection timepoints to assess the initial rate of BCR-ABL1 decline and the controversial suggestion that methods be changed to accommodate this analysis are discussed.
References
More filters
Journal ArticleDOI
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Hagop M. Kantarjian,Neil P. Shah,Andreas Hochhaus,Jorge E. Cortes,Sandip Shah,Manuel Ayala,Beatriz Moiraghi,Zhixiang Shen,Jiri Mayer,Ricardo Pasquini,Hirohisa Nakamae,Françoise Huguet,Concepción Boqué,Charles Chuah,Eric Bleickardt,M. Brigid Bradley-Garelik,Chao Zhu,Ted Szatrowski,David Shapiro,Michele Baccarani +19 more
TL;DR: Since achieving complete cytogenetic response within 12 months has been associated with better long-term, progression-free survival, dasatinib may improve the long- term outcomes among patients with newly diagnosed chronic-phase CML.